Compare · AZN vs FRMM
AZN vs FRMM
Side-by-side comparison of AstraZeneca PLC (AZN) and Forum Markets Incorporated (FRMM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZN and FRMM operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN is the larger of the two at $262.48B, about 3420.8x FRMM ($76.7M).
- Over the past year, AZN is down 10.2% and FRMM is down 81.4% - AZN leads by 71.2 points.
- FRMM has been more active in the news (10 items in the past 4 weeks vs 7 for AZN).
- AZN has more recent analyst coverage (25 ratings vs 1 for FRMM).
- Company
- AstraZeneca PLC
- Forum Markets Incorporated
- Price
- $169.00+0.41%
- $5.66-1.74%
- Market cap
- $262.48B
- $76.7M
- 1M return
- -7.41%
- +12.30%
- 1Y return
- -10.25%
- -81.44%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2026
- 2017
- News (4w)
- 7
- 10
- Recent ratings
- 25
- 1
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Latest AZN
- Enhertu® Plus Pertuzumab Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with HER2 Positive Metastatic Breast Cancer
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- AstraZeneca downgraded by HSBC Securities
- SEC Form 6-K filed by AstraZeneca PLC
- Officer Sharma Mani was granted 2 units of Ordinary Shares, increasing direct ownership by 0.01% to 19,265 units (SEC Form 4)
- The Quantum Sector Hits an Inflection Point: Federal Money, Real Milestones, and a Security Race Running in Parallel
- Abbisko Therapeutics and AstraZeneca Enter a Strategic Collaboration to Conduct the Clinical Trial of Lumipodlin (ABSK043), a First-in-Class Oral PD-L1 Inhibitor, in Combination with TAGRISSO® for NSCLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
Latest FRMM
- Large owner Lomashuk Konstantin sold $1,500,000 worth of shares (250,000 units at $6.00) (SEC Form 4)
- Forum Markets to Present Company Strategy and Business Model at Force Family Office Investor Webinar
- Large owner Lomashuk Konstantin sold $16,141 worth of shares (2,562 units at $6.30) (SEC Form 4)
- Forum Markets Incorporated filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
- Forum Markets Acquires Aircraft Engine for Approximately $12 Million, Advances Plan to Expand Aviation Portfolio to Five Engines
- Large owner Lomashuk Konstantin sold $20,846 worth of shares (3,387 units at $6.15) (SEC Form 4)
- Large owner Lomashuk Konstantin sold $30,477 worth of shares (4,802 units at $6.35) (SEC Form 4)
- SEC Form DEFA14A filed by Forum Markets Incorporated
- SEC Form DEF 14A filed by Forum Markets Incorporated
- New insider Pemble Brian James claimed ownership of 1,451,714 shares (SEC Form 3)